OCTOCELLS

The world urgently needs new ways to produce food, materials, and medicines that are both sustainable and efficient.Traditional production chains still depend on animal-derived inputs and energy-intensive processes that strain natural resources and ecosystems.

Cellular bioproduction offers a powerful alternative, enabling the creation of proteins, tissues, and active ingredients without livestock or overexploitation of land and water. However, this emerging field faces key barriers — cost, scalability, and reproducibility — that limit its industrial adoption.

Octocells addresses these challenges by building eco-friendly, large-scale bioproduction systems that can transform global value chains across healthcare, nutrition, and biomaterials.
 

At the heart of Octocells lies the CellSpace HA™ platform: an animal-free, bioactive hyaluronic acid scaffold for scalable 3D cell growth.

• Up to 200× higher cell output
• 85% cost reduction in cultivated protein production
• Consistent, reproducible quality with no batch-to-batch variation
• Compatible with formats from T25 to T225 flasks
• This disruptive platform enables cost-effective, ethical, and scalable production across multiple markets — from cultivated proteins to tissue engineering and bioactive ingredients.

Aligned with several United Nations Sustainable Development Goals (SDGs), Octocells is committed to reshaping bioproduction for the benefit of people and the planet:

• SDG 2: Zero Hunger
  Scaling cultivated proteins to make sustainable, affordable, and healthy food for all, reducing pressure on land- and animal-based supply chains.
• SDG 3: Good Health and Well-being
  Animal-free, reproducible cell culture systems that lower contamination risk and support safe biotherapies, nutrition, and cosmetics.
• SDG 13: Climate Action
  Lower CO₂ footprint by replacing resource-intensive livestock inputs with clean, efficient bioproduction and localized manufacturing.
• SDG 14: Life Below Water
  Reduced reliance on overfishing and less nutrient runoff, easing pressure on marine ecosystems through alternative, land-based production.
• SDG 15: Life on Land
  Biodiversity protection via alternatives to intensive farming, decreasing land use and deforestation drivers.

Octocells plans to leverage Dassault Systèmes' 3DEXPERIENCE platform to create a digital twin of its bioreactor, enabling the simulation and optimization of both physical and biochemical conditions throughout the production process.

In parallel, the company aims to design a virtual factory connected to its real facility, streamlining operations, maintenance, training, and daily activities. This approach complements Octocells’ next-generation bioproduction platform, which integrates advanced bioreactor technology specifically optimized for high-density cell culture.
 

The founding team of Octocells brings together diverse backgrounds in biology, finance, and data science, fostering a strong multidisciplinary approach. Led by CEO & CSO Zied Souguir, whose experience in the biopharmaceutical sector reflects deep ties to scientific research, the team collectively represents over 50 years of expertise in chemistry, biology, artificial intelligence, and marketing.

To accelerate its growth, Octocells is actively recruiting additional experts in biology and production, engaging in discussions with industry leaders and specialists, and seeking strategic partnerships to strengthen and scale its innovations.